ArticleJournal of neuro-oncology2016
IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Malignant Progression of Diffuse Low-grade Gliomas: A Systematic Review and Meta-analysis on Incidence and Related Factors.Neurologia medico-chirurgica · 2022Pooled it
- Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.Neuro-oncology · 2017Trial
- Malignant transformation in IDH-mutant gliomas: clinical drivers and survival outcomes in a histologically defined cohort.Journal of neuro-oncology · 2026Article
- Machine learning-based MRI radiomics predict IL18 expression and overall survival of low-grade glioma patients.NPJ precision oncology · 2025Article
- A patient-derived cell model for malignant transformation in IDH-mutant glioma.Acta neuropathologica communications · 2024Article
- Tumor radiogenomics in gliomas with Bayesian layered variable selection.Medical image analysis · 2023Article
- Characterization and clinical implications of different malignant transformation patterns in diffuse low-grade gliomas.Cancer science · 2023Article
- Pediatric and Adult Low-Grade Gliomas: Where Do the Differences Lie?Children (Basel, Switzerland) · 2021Review
- Molecular Stratification of Childhood Ependymomas as a Basis for Personalized Diagnostics and Treatment.Cancers · 2021Review
- D-2-Hydroxyglutarate in Glioma Biology.Cells · 2021Review
- Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.The Journal of clinical investigation · 2021Article
- Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer.Frontiers in oncology · 2021Review
- Article
- Prospects of biological and synthetic pharmacotherapies for glioblastoma.Expert opinion on biological therapy · 2020Review
- Metformin as Potential Therapy for High-Grade Glioma.Cancers · 2020Article
- Identification and Validation of an Energy Metabolism-Related lncRNA-mRNA Signature for Lower-Grade Glioma.BioMed research international · 2020Article
- Clinical management and genomic profiling of pediatric low-grade gliomas in Saudi Arabia.PloS one · 2020Article
- IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.Science translational medicine · 2019Article
- Glutathione S-transferase genes variants and glioma risk: A case-control and meta-analysis study.Journal of Cancer · 2019Article
- Temozolomide-associated hypermutation in gliomas.Neuro-oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acquisition of IDH1 or IDH2 mutation (IDHmut) is among the earliest genetic events that take place in the development of most low-grade glioma (LGG). IDHmut has been associated with longer overall patient survival. However, its impact on malignant transformation (MT) remains to be defined. A collection of 210 archived adult LGG previously stratified by IDHmut, MGMT methylation (MGMTmet), 1p/19q combined loss of heterozygosity (1p19qloh) and TP53 immunopositivity (TP53pos) status was analyzed. We used multistate models to assess MT-free survival, considering one initial, one transient (MT), and one absorbing state (death). Missing explanatory variables were multiply imputed. Overall, although associated with a lower risk of death (HR(DEATH) = 0.35, P = 0.0023), IDHmut had a non-significantly higher risk of MT (HR(MT) = 1.84; P = 0.1683) compared to IDH wild type (IDHwt). The double combination of IDHmut and MGMTmet and the triple combination of IDHmut, MGMTmet and 1p/19qloh, despite significantly lower hazards for death (HR(DEATH) versus IDHwt: 0.35, P = 0.0194 and 0.15, P = 0.0008, respectively), had non-significantly different hazards for MT. Conversely, the triple combination of IDHmut/MGMTmet/TP53pos, with a non-significantly different hazard for death, had a significantly higher hazard for MT than IDHwt (HR(MT) versus IDHwt: 2.83; P = 0.0452). Although IDHmut status is associated with longer overall patient survival, all IDHmut/MGMTmet subsets consistently showed higher risks of MT than of death, compared to IDHwt LGG. This supports the findings that molecular events relevant to IDH mutations impact early glioma development prior to malignant transformation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.